Bio-Rad Laboratories, Inc.BIONYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -2.01% | -4.16% | +2.06% | +0.50% | +3.85% |
| Gross Profit Growth | -6.56% | -6.27% | -2.76% | -3.51% | +0.96% |
| EBITDA Growth | -271.62% | -75.78% | +0.00% | -86.93% | +0.00% |
| Operating Income Growth | -40.35% | -54.43% | -24.04% | +3.00% | +6.12% |
| Net Income Growth | -304.69% | -83.33% | +0.00% | -152.34% | +0.00% |
| EPS Growth | -310.45% | -82.99% | +0.00% | -154.34% | +0.00% |
| EPS Diluted Growth | -310.63% | -82.97% | +0.00% | -154.41% | +0.00% |
| Weighted Average Shares Growth | -2.76% | -2.02% | -4.12% | -3.67% | -3.65% |
| Weighted Average Shares Diluted Growth | -2.84% | -2.04% | -4.11% | -3.79% | -3.52% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +53.19% | +86.12% | +19.31% | -26.10% | +32.82% |
| Free Cash Flow Growth | +109.39% | +222.46% | +27.88% | -10.77% | +46.59% |
| Receivables Growth | -7.47% | -4.52% | +5.48% | +2.65% | +4.42% |
| Inventory Growth | -2.63% | +0.86% | -0.61% | -2.62% | -2.54% |
| Asset Growth | -23.86% | -24.45% | +5.43% | -8.55% | +12.95% |
| Book Value per Share Growth | -22.71% | -24.68% | +9.68% | -6.60% | +17.76% |
| Debt Growth | -2.19% | -2.16% | +0.99% | +0.52% | +11.37% |
| R&D Expense Growth | +27.99% | +14.89% | +2.02% | -21.65% | -17.49% |
| SG&A Expenses Growth | -0.92% | -0.80% | +5.91% | +3.17% | +6.18% |